1.Risk factor for occlusion of central venous access port system in colon cancer patients
Hisakazu Nishimori ; Noriko Kouge ; Hitomi Nishimoto ; Yuko Tsuyumu ; Yukie Matsushima ; Megumi Kuyama ; Megumi Fukutake ; Yoshiko Inoue ; Momoe Fujita ; Taizo Hirata ; Katsuyuki Hotta ; Masahiro Tabata
Palliative Care Research 2013;8(1):135-141
Purpose: It is critical to reduce complications associated with the central venous access port (CV-port) system for patients who were treated with chemotherapy or palliative care. Methods: From October 2006 to December 2011, 68 colon cancer patients who were treated with outpatient chemotherapy via a CV-port in the Center for Clinical Oncology, Okayama University Hospital, were analyzed retrospectively. Results: CV-port related complications occurred in 20 (29.4%) patients. No blood could be aspirated in 15 patients when treated via a CV-port. Among the patients with no blood aspiration from their CV-port, ten cases had no complications other than failure of blood aspiration, and anticancer agents have been successfully administered. However, the other five patients had their CV-port system replaced due to complications. Subclavian and left side insertions were the risk factors for catheter occlusion or inability to aspirate blood. Conclusion: Medical staffs should be aware that approximately one-third of the cases with no blood aspiration potentially have troubles with their CV-ports that need to be replaced.
2.A Case of Chronic Kidney Disease Stage G4 Successfully Treated with Yojinkodakuto
Hirofumi HIRANA ; Kazuhiko SHIMIZU ; Akihiro FUTAMURA ; Kazuyuki HIRATANI ; Yukie INOUE ; Keiko OGAWA
Kampo Medicine 2023;74(4):353-364
We report a case of 2X-year-old man with G4 chronic kidney disease (CKD G4). He had a decline in estimated glomerular filtration rate (eGFR) after the initiation of BEP (cisplatin, etoposide, bleomycin) therapy followed by VelP (ifosfamide, cisplatin, vinblastine) therapy for mixed germ cell testicular tumor. The patient’s eGFR did not recover during 59 months after chemotherapy, but showed a tendency to improve after treatment with yojinkodakuto. Yojinkodakuto was prepared by the IPCD (immersing powdered crude drugs) method. The IPCD method was adopted to ensure convenience and good quality prescription herbal medicines. Although eGFR fluctuated after yojinkodakuto treatment, at 3 years, serum creatinine (sCr) and eGFR progressed well, with sCr reducing from 3.98 mg/dL at initiation to 2.6 mg/dL and eGFR increasing from 16 mL/min/1.73 m2 to 25.4 mL/min/1.73 m2. In addition, a long-term eGFR plot analysis confirmed the 3-year improvement trend.